system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
applicable (but, for clarity, except with respect to [***]), (b) all Clinical Data and other Information required to be delivered to AbbVie pursuant to Section 1.112 in order for AbbVie to determine whether to exercise the License Option, and (c) all Information to be included in the Final Development Report (i.e. as a result of - 9 - Source: HARPOON THERAPEUTICS, INC., 10-K, 3/12/2020 activities conducted after the delivery of the Opt-In Development Report), which Initial Development Plan is attached as Schedule 1.84, as the same may be amended from time to time in accordance with the terms hereof. 1.85 "Initiation" or "Initiate" means, with respect to a Clinical Study, the first dosing of the first human subject in such Clinical Study. 1.86 "Intellectual Property" has the meaning set forth in Section 12.5.1. 1.87 "Joint Governance Committee" or "JGC" has the meaning set forth in Section 2.1.1. 1.88 "Joint Intellectual Property Rights" has the meaning set forth in Section 7.1.2. 1.89 "Joint Know-How" has the meaning set forth in Section 7.1.2. 1.90 "Joint Patents" has the meaning set forth in Section 7.1.2. 1.91 "Knowledge" means [***] of the [***] of a Party, or any personnel holding positions equivalent to such job titles (but only to the extent such positions exist at such Party). 1.92 [***] 1.93 [***] 1.94 [***] 1.95 "License Option" has the meaning set forth in Section 3.2.3. 1.96 "License Option Exercise Closing Date" has the meaning set forth in Section 3.2.4. 1.97 "License Option Exercise Notice" has the meaning set forth in Section 3.2.3. 1.98 "License Option Period" has the meaning set forth in Section 3.2.3. 1.99 "Licensed Compound" means (a) the compound known as HPN217 (as described on Schedule 1.99), [***]. 1.100 "Licensed Product" means any product, or portion thereof, containing a Licensed Compound, alone or in combination with one (1) or more other active ingredients, in any and all forms, in - 10 - Source: HARPOON THERAPEUTICS, INC., 10-K, 3/12/2020 current and future formulations, dosages forms and strengths, and delivery modes, including any improvements thereto. For clarity, Licensed Products that contain the same Licensed Compound (whether or not with one or more active ingredients (if applicable)), but in a different formulation, dosage form or delivery device, shall be considered the same Licensed Product for the purposes of calculating milestone and royalty payments hereunder. 1.101 "Losses" has the meaning set forth in Section 11.1. 1.102 "MAA" has the meaning set forth in the definition of "Drug Approval Application." 1.103 "Major Market" means each of [***]. 1.104 "Major Regulatory Filing" means major regulatory filings and documents (including INDs, Drug Approval Applications, material labeling supplements, Regulatory Authority meeting requests, and core data sheets). 1.105 "Manufacture" and "Manufacturing" means all activities related to the synthesis, making, production, processing, purifying, formulating, filling, finishing, packaging, labeling, shipping, and holding of the Licensed Compound, any Licensed Product, or any intermediate thereof, including process development, process qualification and validation, scale-up, pre- clinical, clinical and commercial production and analytic development, product characterization, stability testing, quality assurance, and quality control. 1.106 "Manufacturing Process" has the meaning set forth in Section 4.6.1. 1.107 "Manufacturing Technology Transfer" has the meaning set forth in Section 4.6.1. 1.108 "Net Sales" means[***] (a) [***] (b) [***] (c) [***] (d) [***] (e) [***] (f) [***] of such Licensed Product and to the extent [***] - 11 - Source: HARPOON THERAPEUTICS, INC., 10-K, 3/12/2020 [***], where for purposes of this Net Sales definition, [***] of such Licensed Product; (g) [***] (h) [***] (i) [***] (j) [***], but which [***]. [***] In the event that a Licensed Product is sold in any country or other jurisdiction [***] (i) [***]. - 12 - Source: HARPOON THERAPEUTICS, INC., 10-K, 3/12/2020 (ii) [***] (iii) [***] (iv) [***]. 1.109 "Non-Breaching Party" has the meaning set forth in Section 12.2.1. 1.110 [***] 1.111 "Opt-In Dataset" has the meaning set forth in the definition of "Opt-In Development Report." 1.112 "Opt-In Development Report" means the written data package delivered by Harpoon to AbbVie and generated from the clinical dataset extracted from the [***] as it exists at the date that is [***] (the "Opt-In Dataset" and such date the "Opt-In Development Report Dataset Cutoff Date"). The Opt-In Dataset will arise from the conduct of the Initial Development Activities and will include information available in the [***] as of the Opt-In Development Report Generation Date related to [***]. In addition to the information and data set forth above based on the Opt-In Dataset, the Opt-In Development Report will include[***]. - 13
"""

Extract the exact clause related to "Audit Rights" from the excerpt above.